Toward the rational design of protein kinase casein kinase-2 inhibitors.
about
Eukaryotic translation-initiation factor eIF2beta binds to protein kinase CK2: effects on CK2alpha activityXrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IVNovel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cellsInhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insightBiochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2Structural and functional insights into the regulation mechanism of CK2 by IP6 and the intrinsically disordered protein Nopp140Functional analysis of protein kinase CK2 of the human malaria parasite Plasmodium falciparumPhosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter.Casein kinase II regulates N-methyl-D-aspartate receptor activity in spinal cords and pain hypersensitivity induced by nerve injury.Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Aloe-emodin, an anthraquinone, in vitro inhibits proliferation and induces apoptosis in human colon carcinoma cells.The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2.Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)Caldesmon as a therapeutic target for proliferative vascular diseases.The DEK nuclear autoantigen is a secreted chemotactic factorThe Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design.Casein kinase 2 binds to the C terminus of Na+/H+ exchanger 3 (NHE3) and stimulates NHE3 basal activity by phosphorylating a separate site in NHE3Casein kinase II inhibition reverses pain hypersensitivity and potentiated spinal N-methyl-D-aspartate receptor activity caused by calcineurin inhibitorStructural and functional determinants of protein kinase CK2α: facts and open questions.Protein kinase CK2 inhibitors: a patent review.Casein kinases as potential therapeutic targets.Quercetin and the ocular surface: What we know and where we are going.Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors.Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case.BMP-2 decreases Mash1 stability by increasing Id1 expression.Phosphorylation of serine 239 of Groucho/TLE1 by protein kinase CK2 is important for inhibition of neuronal differentiation.Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis.Adaptor heat shock protein complex formation regulates trafficking of the asialoglycoprotein receptor.Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2.Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEKProtein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus.Protein kinase CK2 is inhibited by human nucleolar phosphoprotein p140 in an inositol hexakisphosphate-dependent manner.Changes in potassium channel modulation may underlie afterhyperpolarization plasticity in oxytocin neurons during late pregnancy.Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.
P2860
Q24530484-3A8ACDD2-148C-4F6E-B201-7AAD020501B4Q24563248-60137AE7-127B-4748-A244-25B3762C4DBAQ24810649-207CDDCB-4D6D-440C-BFA7-190B8FF2DBDBQ27639922-C30375CE-AF5D-425D-BBC5-E4484095EF1CQ27641451-2B6FCF9E-794D-46DF-AE49-7064EA3E75FAQ27655439-F662A8E6-551B-4466-BBAD-A411678DF2F8Q27680582-EA727E2D-06FA-4C51-9D08-A14B069C2ABBQ27973597-A740D2A1-6759-4B11-8CDF-E50C0EE6E26EQ33204214-937B77BF-065A-4CDA-87D5-7382AB27F0BFQ33943983-C5E493B8-1DA9-4109-8C77-65A92EE9AC63Q33959504-A78CD0ED-BE16-4FD3-9E2C-045D6B684E23Q34122676-426816DB-5FD6-4EE1-8264-81AE8F80BB13Q34410937-85A2158B-87A2-4BFF-853D-48BCE7FA29C4Q34471660-BBF738D2-57AD-4C51-A7BD-D087E51C6FC0Q34573044-F989150D-846E-4399-AC2D-B03AAC6C25EEQ34708624-E9743660-FF5B-4272-9DDF-3BEB85B3C4ACQ35065851-E65FED74-B759-4005-B784-281336A35907Q35221391-9501A547-E100-44E8-9101-E252F59F5A04Q36288208-3F6A5C2B-3768-4093-8387-97A6DF7017A5Q36854915-E2337BDE-EE96-453B-BD2B-038164A6B731Q37707733-7B26DC8D-3AD2-46B4-87A8-3B4E102809FCQ37899062-69E5B56F-EC63-4C53-BF39-E828ADB2836AQ38036342-C53A541A-EB28-46EA-97AE-F66636BB11DDQ38632634-E07C6807-00C3-444F-8D91-EBF74FB5C911Q39068539-D14ABC07-5045-40AE-ABC9-16ED5B4E4C90Q39227396-41F217A4-91FD-4BDC-A6D3-5664C11B1274Q39463136-FEB45EB5-7B29-420B-96E2-F67CBCAE7829Q39551009-05C26005-5052-4C13-A97E-8AD33003F83AQ39609944-8F233963-8D6E-4768-B06A-9232A31BE2A8Q39996530-FE140B0A-175B-48BF-BEC4-57A6BDECC593Q39999063-479D97C5-8B18-49A9-9322-9D2109A599F8Q40262816-B71AC432-E1D0-4DA4-8E01-52CFA0705DF3Q40364751-B33D64A6-55A0-495C-9F6C-468AC9CEBD9FQ40500827-DA189F4B-B85E-4AB8-860C-72C69FBE068AQ41296153-52E510F7-6283-47E9-BC76-EACD2D82A191Q46593528-13802B8D-B6BE-4F81-B43B-1F5C237186DBQ53593999-4F4C85CC-1C46-480F-BE73-B43E2C2C592CQ54121411-B979074B-7E87-469C-8681-88F06D3C5151Q54441106-0C05E10B-C6F6-475F-8682-DB67B8DE8221Q54576031-E77CD7B3-311C-4A36-B19D-25E9BA006BB6
P2860
Toward the rational design of protein kinase casein kinase-2 inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@ast
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@en
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@nl
type
label
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@ast
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@en
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@nl
prefLabel
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@ast
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@en
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@nl
P2093
P50
P1476
Toward the rational design of protein kinase casein kinase-2 inhibitors.
@en
P2093
Flavio Meggio
Giuseppe Zagotto
Lorenzo A Pinna
Roberto Battistutta
P304
P356
10.1016/S0163-7258(02)00185-7
P577
2002-02-01T00:00:00Z